The Effect of Magnesium Replacement Therapy in Altering the Course of Hypocalcaemia Post Total Thyroidectomy in Thyroid Cancer Patients

Not Applicable

• Conditions: Cancer

• Registration Number: PACTR202401789967358
• Lead Sponsor: Dr Ahmed Serag

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-12-11
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

•Patients suffering from hypocalcaemia post total thyroidectomy at National Cancer Institute.
•At least one parathyroid gland must be preserved with normal PTH levels.
•Adults only will be included (age from 18 to 65 years).
•Preoperative serum calcium, magnesium, phosphorus and vitamin D levels are normal in all patients.

Exclusion Criteria

•Infants and children (age < 18 years)
•Elderly (age > 65 years)
•Pregnant women
•Cognitively impaired or mentally disabled subjects
•Patients with history of thyroid surgeries
•All parathyroid glands are lost during surgery
•Severe symptomatic hypocalcaemia needing to be treated with intravenous calcium for emergency expressed as seizures or tetanic convulsions including Trousseau`s sign and Chvostek`s sign (with cut-off point of calcium level < 7 mg/dl)
•Moderate and severe hypomagnesaemia (Mg level < 1.2 mg/dl) or Symptomatic hypomagnesaemia needing to be treated with intravenous magnesium for emergency (but in case of mild asymptomatic hypomagnesaemia in the treatment and the control group no special intervention or exclusion)
•Patients with renal impairment ( Creatinine clearance (Crcl) < 60ml/min )
•Patients with hepatic impairment (Alanine aminotransferase (ALT) > 50 IU/L , Aspartate aminotransaminase (AST) > 40 IU/L and Total bilirubin > 1.2 mg/dl )
•Patients taking any medication that would affect calcium levels such as, Thiazide diuretics, lithium, rifampicin, phenytoin, Bisphosphonates, Dietary supplements containing calcium and vitamins affecting calcium level such as vitamin D, etc.
•patients with other types of cancer other than thyroid cancer (e.g. any metastasis).

Study & Design

• Study Type: Interventional
• Study Design: Not specified